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Abstract
We assess annual costs of screening provision activities implemented by 23 of the Centers for 
Disease Control and Prevention’s Colorectal Cancer Control Program (CRCCP) grantees and 
report differences in costs between colonoscopy and FOBT/FIT-based screening programs. We 
analysed annual cost data for the first three years of the CRCCP (July 2009–June 2011) for each 
screening provision activity and categorized them into clinical and non-clinical screening 
provision activities. The largest cost components for both colonoscopy and FOBT/FIT-based 
programs were screening and diagnostic services, program management, and data collection and 
tracking. During the first 3 years of the CRCCP, the average annual clinical cost for screening and 
diagnostic services per person served was $1150 for colonoscopy programs, compared to $304 for 
FIT/FOBT-based programs. Overall, FOBT/FIT-based programs appear to have slightly higher 
non-clinical costs per person served (average $1018; median $838) than colonoscopy programs 
(average $980; median $686). Colonoscopy-based CRCCP programs have higher clinical costs 
than FOBT/FIT-based programs during the 3-year study timeframe (translating into fewer people 
screened). Non-clinical costs for both approaches are similar and substantial. Future studies of the 
cost-effectiveness of colorectal cancer screening initiatives should consider both clinical and non-
clinical costs.
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1. Introduction
Colorectal cancer (CRC) poses a significant health burden in the United States as it accounts 
for approximately 8 percent of all new cancer cases and nearly 9 percent of all cancer deaths 
☆The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the 
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annually (U.S. Cancer Statistics Working Group, 2015). The United States Preventive 
Services Task Force recommends CRC screening for average-risk individuals aged 50–74 
years (Whitlock, Lin, Liles, Beil, & Fu, 2008) using guaiac based fecal occult blood test 
(FOBT), fecal immunochemical test (FIT), sigmoidoscopy or colonoscopy. FOBTs and FITs 
(hereafter referred to as FOBT/FIT) are recommended annually; sigmoidoscopies are 
recommended every five years in combination with fecal testing every three years; and 
colonoscopies are recommended once every ten years (National Governors Association 
Center for Best Practices, 2008; Rex et al., 2009; Smith et al., 2015; Winawer et al., 2003).
Despite the availability of multiple screening tests for prevention and early detection of 
CRC, the use of CRC screening tests remains suboptimal (Centers for Disease Control and 
Prevention, 2013; Sabatino, White, Thompson, & Klabunde, 2015). In an effort to increase 
screening rates, the Centers for Disease Control and Prevention (CDC) established the 
Colorectal Cancer Control Program (CRCCP), a six-year initiative beginning in 2009. 
Details on the CRCCP are provided elsewhere (Tangka & Subramanian, under review). 
Briefly, the CRCCP-funded 29 grantees with several programs choosing endoscopic tests, 
mostly colonoscopy, with others selecting FOBT/FIT based tests. This difference in 
screening modality across grantee programs provides a natural experiment to assess 
differences in the cost of implementing and providing CRC screening in the CRCCP using 
endoscopy versus FOBT/FIT based tests.
Although both FOBT/FIT and endoscopy-based screening tests are cost-effective approaches 
to screen for CRC (Pignone, Russell, & Wagner, 2005; Vijan et al., 2007; Zauber et al., 
2007), there are some variations in guideline recommendations due to the differences in test 
characteristics (National Governors Association Center for Best Practices, 2008; Rex et al., 
2009; Smith et al., 2015; Winawer et al., 2003). Endoscopic tests allow for prevention via 
identification and removal of precancerous polyps as well as the detection of cancer, while 
FOBT/FIT tests are much less sensitive in detecting polyps and do not allow for removal of 
precancerous polyps unless a follow-up colonoscopy is conducted following positive test 
results (Smith et al., 2015). In addition, although no guidelines have considered cost-
effectiveness in developing recommendations, independent analyses have shown that under 
certain circumstances, the use of FOBT may provide better value than colonoscopy (Fisher, 
Fikry, & Troxel, 2006; Subramanian, Bobashev, & Morris, 2010). Therefore, there is an 
ongoing need to systematically assess potential cost differences between the CRC screening 
modalities.
In this study we assess the differences in clinical and non-clinical screening provision costs 
incurred by colonoscopy-based and FOBT/FIT-based programs during the first 3 years of the 
CRCCP program. No prior study has addressed potential variation in the non-clinical cost of 
managing and operating programs using different CRC screening modalities. Analysis of the 
non-clinical costs of CRCCP implementation offers real-world estimates pooled across 
multiple public health programs. Although the primary focus of this study is on the non-
clinical programmatic costs, we also report the costs of screening and diagnostic services. 
The findings from this study provide an economic evidence-base to inform future program 
funding and resource allocation to scale up public health CRC screening programs to 
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achieve the National Colorectal Cancer Roundtable targeted screening rate of 80% by 2018 
(National Colorectal Cancer Roundtable, n.d.).
2. Methods
2.1. Conceptual framework
To systematically compare the colonoscopy and FOBT/FIT programs, we categorized cost 
into direct clinical, direct non-clinical, and indirect non-clinical costs. Key components of 
these cost categories included the following:
1. Direct clinical services-related activities—provision of screening tests, 
diagnostic services (diagnostic colonoscopy after positive FOBT or FIT), and 
surveillance procedures (follow up procedures after polyp or cancer diagnosis for 
individuals requiring surveillance);
2. Direct non-clinical screening provision activities—managing provider contracts, 
billing systems and other procedures, providing patient navigation and support 
services, providing operations support to providers for screening and diagnostic 
services, and ensuring appropriate treatment for complications and cancers 
(programs do not finance any required treatments); and
3. Indirect non-clinical overarching activities—program management, program 
monitoring and evaluation, and administration.
The details on the program components and the specific activities performed by the CRCCP 
grantees are shown in Appendix A, Fig. A1.
2.2. Data collection process
We used a pre-tested and validated web-based cost assessment tool (CAT) to collect cost and 
resource use data annually from all CRCCP-funded grantees during the first three years of 
the program (July 2009–June 2011). The CAT is based on well-established methods of 
collecting cost data for program evaluation; details on developing, testing and evaluating the 
CAT have been published previously (Drummond, Schulpher, Torrance, O’Brien, & 
Stoddard, 2005; Salome, French, Miller, & McLellan, 2003; Subramanian, Ekwueme, 
Gardner, & Trogdon, 2009). All grantees were trained to input data into the web-based CAT 
and were also provided with a user’s guide and technical assistance to ensure standardized 
reporting. Grantees reported the following information annually: staff salaries, roles and 
percent time spent on the CRCCP; types of screening promotion and screening provision 
activities performed; costs of materials, contracts, and consultants; and costs of overhead 
and administration. We asked grantees to indicate funding amounts supporting their CRCCP 
from the CDC and from other sources, such as the state, as well as to provide in-kind costs 
regarding labor, materials, and contracts.
We collected data on direct clinical, direct non-clinical, and indirect non-clinical costs. 
Patient navigation was not collected as a separate activity until year 2; some year 1 patient 
navigation costs may have been reported under other activities but since the average start-up 
time to begin screening was 9 months, only a small amount of expenditure was incurred for 
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these activities in year 1. We collected information in the CAT to allow us to separate out the 
proportion of these overarching activities that supported screening promotion and screening 
provision activities. Promotion activities and cost are summarized in a companion 
manuscript (Tangka et al., 2016). Each year we prepared summaries of the CAT for each 
grantee to review for accuracy and approve. In a few instances, programs were unable to 
separate costs into the specific activities and these costs are reported as ‘other costs.’
In addition to the cost data, the grantees submitted detailed person-level data on screening 
and surveillance services provided by the grantee programs. Clinical activities funded 
directly by CDC were reported using the Colorectal Cancer Clinical Data Elements 
(CCDEs) and those funded through other sources were reported in the CAT using the same 
standardized definitions. The data elements include type of screening test, proportion 
receiving a diagnostic follow-up procedure and procedure type, polyps identified and 
cancers detected. Details on the CCDEs and definitions used for the data elements have been 
reported previously (Seeff & Rohan, 2013).
2.3. Analytic framework and approach
We present details on cost and resource use stratified by programs that provided 
colonoscopies versus FOBT/FIT-based testing. All the programs offered colonoscopy for 
diagnostic follow-up after a positive FOBT/FIT result. Several programs offered 
colonoscopy screening for increased risk individuals as recommended by guidelines and 
some programs offered stool tests as an alternative to colonoscopy (Rex et al., 2009; Smith 
et al., 2015). We classified colonoscopy programs as those programs that provided more 
than 85% of their screens using colonoscopy or sigmoidoscopy, and classified FOBT/FIT 
program similarly. We excluded 5 programs from the analysis as they offered mixed 
screening or switched modalities during the first three years of the CRCCP and one program 
did not report cost for screening tests during the study period.
To compare across the 14 colonoscopy and 9 FOBT/FIT-based programs we provide 
descriptive statistics on the number of screens provided, diagnostic follow-up tests and 
polyps or cancers identified. We report mean and median costs for each screening provision 
activity stratified by type of screening program. The costs are also reported in the broad 
categories of direct non-clinical screening provision activities, indirect non-clinical 
overarching activities and clinical services-related activities. Median costs are presented 
along with the average as there are large variations in the costs reported across the programs. 
In-kind contributions are included in all estimates. We also provide the proportion of in-kind 
contributions made to the grantee program by activity. To assess potential variation across 
the program years, we show annual costs by activity and, finally, we compare the average 
costs and cost per person served for each activity between the colonoscopy and FOBT/FIT-
based programs. All costs are reported from a program perspective and have not been 
adjusted for cost of living differences. Past analysis has shown that adjustments using 
regional cost-of-living index do not adequately control for differences (Subramanian, 
Ekwueme, Gardner, Bapat, & Kramer, 2008). Furthermore, the geographic distribution of 
the programs is not substantially different. On a per person basis, we would consider even a 
$20 difference in specific costs of program activities as meaningful (even if not statistically 
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significant) as this would result in substantial cost for programs serving a large volume of 
individuals. For example, if 1000 individuals are screened, the difference in cost would be 
$20,000.
3. Results
Table 1 provides descriptive statistics on the clinical services provided through the 
colonoscopy and FOBT/FIT-based programs. On average, the FOBT/FIT-based programs 
screened more individuals than colonoscopy programs (mean of 1471 versus 879) but the 
median values were similar. Diagnostic follow-up tests were much higher in the FOBT/FIT-
based group; this is expected as colonoscopy follow-up would be required for all persons 
with a positive initial screening test. The surveillance colonoscopies were provided to a large 
proportion of individuals in colonoscopy programs compared to the FOBT/FIT-based 
programs (891 individuals versus 429). The number of polyps identified was also 
substantially higher in the colonoscopy programs with 3899 polyps compared to 983 polyps 
for the FOBT/FIT-based programs. Overall, 48 colorectal cancers were identified in the 
colonoscopy group and 32 cancers in the FOBT/FIT-based program.
Fig. 1 provides the percent distribution of cost across all activities performed by the 
colonoscopy and FOBT/FIT-based programs. (Appendix A, Table A1 presents the average 
and median costs along with the proportion of in-kind contributions for each activity.) The 
largest cost components for both types of programs were clinical services related to 
screening and diagnostic services, followed by program management and then data 
collection and tracking. Total screening and diagnostic costs were 1.9 times higher for the 
colonoscopy programs compared to FOBT/FIT-based programs (average of $754,228 
compared to $405,791) (Appendix A, Table A1). There was also a large difference in mean 
program management costs, but the median costs were similar indicating that this variation 
is likely due to a few outliers and not a systematic difference between the groups. The mean 
expenditure on quality assurance and professional development was 2.5 times higher for the 
FOBT/FIT-based programs, but again, comparison based on the median showed difference 
was reduced to 1.4 times higher (median of $39,158 versus $27,326). There were also 
differences for direct non-clinical screening provision activities, with 1.6 times higher 
expenditure incurred by FOBT/FIT-based programs for provider contract management 
(mean of $76,495 compared to $46,625 for colonoscopy-based programs) but colonoscopy 
programs had higher mean expenditure for all other direct non-clinical screening provision 
activities (although there is variation in the median costs). Patient navigation and provider 
support cost estimates indicate extensive variation across grantee programs, but cost related 
to ensuring treatment for complications and cancers was 2.6 times higher for colonoscopy 
programs. The proportion of in-kind contributions varied across program activities for both 
groups and there were no consistent patterns.
Fig. 2 presents the median cost for each of the three program years separately to identify 
patterns in the distribution of expenditure over time. Both screening and surveillance costs 
were higher in years 2 and 3 compared to year 1 due to the increase in individuals screened 
over time. The number of individuals screened across the FOBT/FIT-based programs in the 
first year was 2365 and this increased to 6197 in the third year. For colonoscopy programs 
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the screening numbers were 2723 and 4700 in the first and third years (data not shown in 
figure). For both colonoscopy and FOBT/FIT-based programs, the direct non-clinical 
screening provision costs increased over time, again likely reflecting the increase in 
individuals screened. Program management costs for FOBT/FIT-based programs declined 
steeply over the three year period while expenditures for other activities (for example, data 
collection and tracking, administration) generally showed less variation.
Table 2 presents the mean cost per person served by the programs with median cost reported 
in brackets. Clinical cost for screening and diagnostic services was $1150 on average for 
colonoscopy programs and $304 for FOBT/FIT-based programs, again showing variation 
across programs. Surveillance cost per person served was variable with an average cost of 
$1131 and $588 for colonoscopy and FOBT/FIT-based programs, respectively. The average 
per person direct non-clinical cost was $363 for colonoscopy programs and $225 for FOBT/
FIT-based programs. The median costs of the programs were closer in range, indicating 
substantial variation across the colonoscopy programs; overall, the median costs were lower 
for colonoscopy programs compared to the FOBT/FIT-based programs ($211 versus $247). 
The indirect non-clinical overarching costs also showed variation, with a total mean non-
clinical cost (direct and indirect) of about $1000 for both types of programs; however, 
median costs were lower for the colonoscopy programs. The cost of provider contract 
management was higher for FOBT/FIT-based programs while the cost of patient navigation 
was higher for colonoscopy programs. The largest per person indirect non-clinical cost by 
specific activity was program management; mean management cost was $188 for 
colonoscopy programs and $265 for FOBT/FIT-based programs (median values were 
similar).
4. Discussion
We compared the clinical and non-clinical costs of 14 colonoscopy and 9 FOBT/FIT-based 
programs that were funded by the CRCCP. On average, about $1000 per person was 
expended on direct and indirect non-clinical activities. Although the median non-clinical 
costs are somewhat lower, they are still substantial at about $700–$800 per person. A key 
finding from this study is that CRC programs incur substantial non-clinical costs that should 
be taken into account when planning future programs.
Additionally, the clinical cost of colonoscopy is almost four times the cost of FOBT/FIT per 
person when screening and diagnostic follow up tests are taken into account. Therefore, 
programs that use colonoscopy will only be able to screen about one-fourth the number of 
individuals during the early years of the program. As the colonoscopy screening interval is 
every 10 years compared to every year for FOBT/FIT, the numbers screened will converge 
over time but the initial screen will be delayed in the colonoscopy versus FOBT/FIT 
programs. When the goal is to offer first-time screening to a large cohort of individuals over 
a short period of time, FOBT/FIT tests would be the preferred approach.
The indirect overarching component (which is included in the total non-clinical cost) was 
about $475–$793 per person served for both types of programs. These costs are likely to 
decrease if programs expand to cover a large cohort of individuals as economies of scale are 
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achieved. Additionally, previous research has shown that there are substantial fixed and start-
up costs involved with program operations (Ekwueme et al., 2014; Subramanian et al., 2013; 
Trogdon, Ekwueme, Subramanian, & Crouse, 2014). Therefore, the indirect overarching 
cost should decline on a per person basis as more individuals are screened, but it is unclear 
to what extent these costs are fixed versus semi-variable.
Surveillance cost, which is an expenditure related to colonoscopy, showed large variation 
with the mean of about $600 and $1100 per person, respectfully, for the FOBT/FIT-based 
and colonoscopy programs. This wide variation in the unit cost of tests and procedures 
between grantees was also reported in prior analysis of CDC’s Colorectal Cancer Screening 
Demonstration Program (CRCSDP) and variation in clinical costs were also present in 
screening programs for breast and cervical cancer (Subramanian et al., 2008; Tangka et al., 
2013). In the CRCSDP, the cost of FOBT screening ranged from $48 to $149 and 
colonoscopy screening ranged from $654 to $1600 per patient. Although grantees are 
required to reimburse for clinical services within Medicare rates, the actual costs of the 
clinical services are highly dependent on the ability to negotiate payment rates with 
providers. Therefore, the actual cost of the clinical services is dependent on provider supply, 
anticipated screening volume, and other factors specific to a given setting.
The strength of the present cost analysis is that we were able to systematically collect and 
quantify resources, and analyze expenditures from 23 CRCCP programs. We used consistent 
definitions for activities and a pre-tested data collection tool. Despite these methodological 
advantages there are several potential limitations. First, in the real world setting, programs 
may provide more than one type of screening test as they need to accommodate patient 
preferences and also follow guideline recommendations for screening individuals at 
increased and high risk. Second, we use program year to assess potential year-to-year 
variation, but programs generally operate on a continuous basis and therefore screening tests 
could be performed in one year while diagnostic follow-up and treatment, if required, could 
be provided in the subsequent year. Therefore, classification of costs and screens into 
specific time periods are not always accurate. Likewise, the study assesses cost per year and 
does not account for cost per patient over an extended period of time to compare long-term 
cost of colonoscopy versus FOBT/FIT-based programs. We report cost for only the first 
three years of the CRCCP and there could have been changes in the program costs after the 
data collection time period. Third, we report average and median costs to account for 
variation across programs but the differences in grantees across the two groups of screening 
programs, colonoscopy versus FOBT/FIT-based, could still influence the costs reported. 
Future research should systematically assess the factors that can explain the differences in 
cost of specific program activities across CRC screening programs.
5. Conclusions and lessons learned
Our analysis of the activity-based cost data from the first three years of the CRCCP reveal 
that the choice of FOBT/FIT versus colonoscopy will significantly impact the timeliness of 
the initial screen offered as a much larger number of individuals can be screened quicker 
with lower cost FOBT/FIT than colonoscopy. In addition, CRC screening programs incur 
substantial non-clinical costs, regardless of whether the program is colonoscopy or FOBT/
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FIT-based. Future studies of the cost-effectiveness of CRC screening programs should 
consider both these clinical and non-clinical costs in planning program implementation.
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Appendix A
See Fig. A1 and Table A1.
Fig. A1. 
CRCCP Screening Provision Program Components and Specific Activities*.
CRCCP Colorectal Cancer Control Program
* Screening promotion activities are reported in a companion manuscript (20)
** Overarching component supports screening provision and screening promotion activities; 
the costs of the overarching component assigned to screening provision are reported in this 
study.
*** For example, support activities such as information management.
Table A1
Mean, Median, and in-Kind Cost for Program Activities by Screening Tests.
Colonoscopy Programs FOBT/FIT-based Programs.
Mean (Median) of 
Years 1–3
% in-kind costs Mean (Median) of 
Years 1–3
% in-kind costs
Clinical Services Related Activities
Screening and diagnosis 
costs
$754,228 (700,213) 18% $405,791 (252,358) 23%
Surveillance (only 
programs with 
surveillance)
$76,745 (63,309) 0% $34,726 (41,371) 8%
Direct Non-Clinical Screening Provision Activities
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Colonoscopy Programs FOBT/FIT-based Programs.
Mean (Median) of 
Years 1–3
% in-kind costs Mean (Median) of 
Years 1–3
% in-kind costs
Manage provider 
contracts, billing 
systems and other 
procedures
$46,625 (46,250) 5% $76,495 (68,824) 4%
Provide patient 
navigation and support 
services
$97,393 (35,061) 14% $54,747 (49,290) 1%
Provide support to 
providers for screening 
and diagnostic services
$60,079 (9708) 36% $11,159 (1315) 0%
Ensure appropriate 
treatment for 
complications and 
cancers
$41,026 (21,118) 2% $15,893 (13,493) 16%
Other screening 
provision activities
$22,305 (2667) 6% $9,945 (1276) 1%
Indirect Non-Clinical Overarching Activities
Program management $142,231 (123,403) 18% $275,863 (129,547) 9%
Quality assurance and 
professional 
development
$35,149 (27,326) 6% $90,760 (39,158) 52%
Partnership 
development and 
maintenance
$21,663 (17,407) 6% $26,607 (20,924) 0%
Data collection and 
tracking
$105,079 (75,265) 2% $97,063 (83,968) 4%
Program monitoring 
and evaluation
$44,281 (36,684) 2% $54,836 (26,214) 14%
Other activities $11,146 (1141) 62% $23,571 (5340) 4%
Administration $82,001 (44,574) 15% $80,793 (82,662) 0%
FOBT fecal occult blood test; FIT fecal immunochemical test. Note: Other activities include costs that could not be 
separated into specific activities.
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Fig. 1. 
Percent Distribution of Costs for Program Activities by Screening Tests.
FOBT fecal occult blood test; FIT fecal immunochemical test
Note: Other activities include costs that could not be separated into specific activities
Subramanian et al. Page 12
Eval Program Plann. Author manuscript; available in PMC 2018 March 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 2. 
Median Cost by Activity for Each of the Three Years of the CRCCP.
Note: Patient navigation cost only collected in year 2 and year 3. Other activities include 
costs that could not be separated into specific activities. The number of individuals screened 
in the FOBT/FIT based programs in first year was 2,365 and this increased to 6,197 in the 
third year. Correspondingly, for colonoscopy programs the screening numbers were 2,723 
and 4,700.
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CRCCP Colorectal Cancer Control Program; FOBT fecal occult blood test; FIT fecal 
immunochemical test
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Table 1
Comparison of CRCCP Screening Tests, Diagnostic Services, and Cancers Detected, 2009–2011.
Colonoscopy Programs FOBT/FIT-based Programs
Number of programs (N) 14 9
Total individuals screened (N)a 12,309 13,243
Mean per program (median) 879 (801) 1471 (811)
Total screening tests (N) 12,407 13,327
Mean per program (median) 886 (806) 1,481 (811)
Total diagnostic follow-up tests (N) 346 841
Mean per program (median) 25 (17) 93 (25)
Under surveillance (N)b 891 429
Mean per program (median) 64 (21) 48 (15)
Polyps (N) 3,899 983
Mean per program (median) 279 (176) 109 (36)
Cancers detected (N) 48 32
Mean per program (median) 3 (2) 4 (2)
CRCCP Colorectal Cancer Control Program; FOBT fecal occult blood test; FIT fecal immunochemical test.
a
Total of unduplicated individuals screened per year.
b
Total number of individuals undergoing surveillance.
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Table 2
Mean Cost (with median) per Person Served by the Programs.
Colonoscopy Programs ($) FOBT/FIT-based Programs ($)
Clinical Services Related Activities 1,634 (1,876) 630 (618)
Screening and diagnosis costs 1,150 (853) 304 (275)
Surveillance (only programs with surveillance) 1,131 (1,056) 588 (517)
Direct Non-Clinical Screening Provision Activities 363 (211) 225 (247)
Manage provider contracts and billing systems 62 (52) 102 (77)
Provide patient navigation and support services 101 (47) 68 (36)
Provide support to providers for screening and diagnostic services 75 (11) 17 (1)
Ensure appropriate treatment for complications and cancers 47 (17) 22 (4)
Other screening provision activities 78 (3) 17 (2)
Indirect Non-Clinical Overarching Activities 617 (475) 793 (591)
Program management 188 (150) 265 (146)
Quality assurance and professional development 62 (32) 158 (42)
Partnership development and maintenance 45 (17) 31 (18)
Data collection and tracking 111 (99) 135 (30)
Program monitoring and evaluation 83 (48) 73 (31)
Other activities 10 (1) 31 (8)
Administration 118 (96) 99 (93)
Note: FOBT fecal occult blood test; FIT fecal immunochemical test. Other activities include costs that could not be separated into specific 
activities.
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